Multildrug resistance mechanisms in chronic lymphocytic leukaemia

被引：37

作者：

Consoli, U ^{[1
]}

Santonocito, A ^{[1
]}

Stagno, F ^{[1
]}

Fiumara, P ^{[1
]}

Privitera, A ^{[1
]}

Parisi, G ^{[1
]}

Giustolisi, GM ^{[1
]}

Pavone, B ^{[1
]}

Palumbo, GA ^{[1
]}

Di Raimondo, F ^{[1
]}

Milone, G ^{[1
]}

Guglielmo, P ^{[1
]}

Giustolisi, R ^{[1
]}

机构：

[1] Univ Catania, Chair & Div Haematol Bone Marrow Transplantat, I-95124 Catania, Italy

来源：

BRITISH JOURNAL OF HAEMATOLOGY | 2002年 / 116卷 / 04期

关键词：

multidrug resistance; chronic lymphocytic leukaemia;

D O I：

10.1046/j.0007-1048.2002.03344.x

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

We evaluated the presence of P-glycoprotein (P-gp)-170, multidrug resistance protein (MRP), lung resistance protein (LRP)-56 and Bcl-2 in CD19-positive cells from 100 cases of chronic lymphocytic leukaemia (CLL). P-gp-170 was found in 73% of the CLL cases with no significant difference regarding stage or previous treatment. LRP-56 protein was homogeneously distributed with no differences for stage or treatment. MRP protein was detected at a low level of expression in 49.4% of CLL patients with no differences for stage or treatment. Bcl-2 protein was expressed at a high level in all CLL patients and higher levels were found in the advanced stage. This leads us to conclude that P-gp, MRP, LRP-56 and Bcl-2 are frequently expressed in CLL. P-gp, MRP and LRP are not correlated to stage or previous treatment. Bcl-2 is higher in advanced-stage patients. The clinical and biological significance of these zMDR mechanisms in CLL remains to be fully explained.

引用

页码：774 / 780

页数：7

共 33 条

[1] HIGH MDR1- AND MRP-, BUT LOW TOPOISOMERASE-II ALPHA-GENE EXPRESSION IN B-CELL CHRONIC LYMPHOCYTIC LEUKEMIAS
BECK, J
NIETHAMMER, D
GEKELER, V
[J]. CANCER LETTERS, 1994, 86 (01) : 135 - 142
[2] Beck WT, 1996, CANCER RES, V56, P3010
[3] BURGER H, 1994, LEUKEMIA, V8, P990
[4] HIGH EXPRESSION OF THE MULTIDRUG RESISTANCE-ASSOCIATED PROTEIN (MRP) IN CHRONIC AND PROLYMPHOCYTIC LEUKEMIA
BURGER, H
NOOTER, K
SONNEVELD, P
VANWINGERDEN, KE
ZAMAN, GJR
STOTER, G
[J]. BRITISH JOURNAL OF HAEMATOLOGY, 1994, 88 (02) : 348 - 356
[5] GUIDELINES FOR CLINICAL PROTOCOLS FOR CHRONIC LYMPHOCYTIC-LEUKEMIA - RECOMMENDATIONS OF THE NATIONAL-CANCER-INSTITUTE-SPONSORED-WORKING-GROUP
CHESON, BD
BENNETT, JM
RAI, KR
GREVER, MR
KAY, NE
SCHIFFER, CA
OKEN, MM
KEATING, MJ
BOLDT, DH
KEMPIN, SJ
FOON, KA
[J]. AMERICAN JOURNAL OF HEMATOLOGY, 1988, 29 (03) : 152 - 163
[6] The novel anthracycline annamycin is not affected by P-glycoprotein-related multidrug resistance: Comparison with idarubicin and doxorubicin in HL-60 leukemia cell lines
Consoli, U
Priebe, W
Ling, YH
Mahadevia, R
Griffin, M
Zhao, S
PerezSoler, R
Andreeff, M
[J]. BLOOD, 1996, 88 (02) : 633 - 644
[7] Differential induction of apoptosis by fludarabine monophosphate in leukemic B and normal T cells in chronic lymphocytic leukemia
Consoli, U
El-Tounsi, I
Sandoval, A
Snell, V
Kleine, HD
Brown, W
Robinson, JR
DiRaimondo, F
Plunkett, W
Andreeff, M
[J]. BLOOD, 1998, 91 (05) : 1742 - 1748
[8] EXPRESSION OF A MULTIDRUG-RESISTANCE GENE IN HUMAN-MALIGNANT LYMPHOMA AND RELATED DISORDERS
DAN, S
ESUMI, M
SAWADA, U
HAYASHI, N
UCHIDA, T
YAMAZAKI, T
ASHIYA, M
SATOH, Y
OHSHIM, T
HORIE, T
TSURUO, T
SHIKATA, T
[J]. LEUKEMIA RESEARCH, 1991, 15 (12) : 1139 - 1143
[9] Involvement of p-glycoprotein in the transmembrane transport of interleukin-2 (IL-2), IL-4, and interferon-gamma in normal human T lymphocytes
Drach, J
Gsur, A
Hamilton, G
Zhao, SR
Angerler, J
Fiegl, M
Zojer, N
Raderer, M
Haberl, I
Andreeff, M
Huber, H
[J]. BLOOD, 1996, 88 (05) : 1747 - 1754
[10] FLENS MJ, 1994, CANCER RES, V54, P4557

← 1 2 3 4 →